HCAT
Health Catalyst, Inc.
HCAT trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over HCAT overall, supported by lower modeled downside and stronger fundamentals.
HCAT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Unavailable |
HCAT's cash flow is currently healthy, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HCAT PE Valuation
HCAT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
HCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect HCAT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over HCAT on the outlook, with more favorable earnings and revenue expectations.
HCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.84 | -$1.25 |
| Q2 2026 | -$3.69 | -$2.18 |
| Q1 2026 | -$3.73 | -$2.58 |
| Q4 2025 | -$2.55 | -$1.40 |
| Q3 2025 | -$1.59 | -$0.25 |
| Q2 2025 | -$1.51 | -$0.02 |
| Q1 2025 | -$1.15 | +$0.69 |
| Q4 2024 | -$1.15 | +$0.94 |
HCAT lost $2.84 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over HCAT on earnings quality, reporting a profit while its opponent remains loss making.
HCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56.3M | -26% |
| Q2 2026 | $70.5M | -13% |
| Q1 2026 | $70.8M | -11% |
| Q4 2025 | $74.7M | -6.2% |
| Q3 2025 | $76.3M | 0% |
| Q2 2025 | $80.7M | +6.3% |
| Q1 2025 | $79.4M | +6.3% |
| Q4 2024 | $79.6M | +6% |
HCAT's revenue has slid since its 2025 peak: $56M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 89% | +112 points |
| Q2 2026 | -52% | -5.8 points |
| Q1 2026 | -150% | -125 points |
| Q4 2025 | -115% | -93 points |
| Q3 2025 | -23% | -5 points |
| Q2 2025 | -46% | -25 points |
| Q1 2025 | -25% | +5.1 points |
| Q4 2024 | -22% | +22 points |
HCAT has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over HCAT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
HCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | -$1.3M |
| Q2 2026 | -$70K | +$8.7M |
| Q1 2026 | $18.2M | +$18.6M |
| Q4 2025 | $9.6M | +$13.6M |
| Q3 2025 | -$719K | -113% |
| Q2 2025 | -$8.8M | -763% |
| Q1 2025 | -$390K | -104% |
| Q4 2024 | -$3.9M | +$15.4M |
HCAT's free cash flow has turned positive again: $26M over the past year, against −$14M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over HCAT on cash flow, with more consistent year-over-year improvement.
HCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +2M shares |
| 1 year | +7.9% | +5.6M shares |
| 3 years | +34% | +19.2M shares |
| 5 years | +55% | +26.9M shares |
| Available history | +105% | +38.8M shares |
HCAT has 76M diluted shares, up 7.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $5M |
| Q4 2024 | — |
HCAT hasn't bought back shares in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over HCAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
HCAT Net Leverage
HCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
HCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.4 | Neutral |
| Stochastic | 9.3 | Oversold |
HCAT's weekly RSI is 37 (neutral) and its Stochastic is 9 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
HCAT PE vs Healthcare Sector
HCAT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
HCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.65 | 18% below |
| 20 week MA | $1.79 | 24% below |
| 50 week MA | $1.79 | 24% below |
| 100 week MA | $2.93 | 54% below |
| 200 week MA | $6.18 | 78% below |
HCAT is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over HCAT on trend strength, trading above more of its moving averages.
HCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.1 | $44.9 | +31% |
| 2021 | $44.9 | $39.5 | -12% |
| 2022 | $39.5 | $10.3 | -74% |
| 2023 | $10.3 | $9.26 | -10% |
| 2024 | $9.26 | $7.08 | -24% |
| 2025 | $7.08 | $2.42 | -66% |
| 2026 YTD | $2.42 | $1.36 | -44% |
HCAT has finished five years in a row lower, and it's down 44% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over HCAT on returns for 2026, with the stronger performance.